Keyphrases
Tumor
76%
Overall Survival
61%
Chemotherapy
49%
Acute Myeloid Leukemia
48%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
45%
Phase II Study
44%
Confidence Interval
41%
Multiple Myeloma
39%
Breast Cancer
38%
Progression-free Survival
36%
Phase II Trial
35%
Non-small Cell Lung Cancer (NSCLC)
34%
Relapsed or Refractory
32%
Granulocyte Colony-stimulating Factor (G-CSF)
29%
Hematopoietic Stem Cells
28%
T Cells
28%
Clinical Trials
28%
In Cancer
27%
Graft-versus-host Disease (GvHD)
25%
Natural Killer Cells
25%
Leukemia
24%
Rituximab
23%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
21%
Hazard Ratio
21%
Bone Marrow
21%
Human Immunodeficiency Virus Type 1 (HIV-1)
19%
Targeted Therapy
19%
Metastatic Breast Cancer
18%
Myelodysplastic Syndrome
18%
Non-Hodgkin Lymphoma
18%
Adverse Events
17%
Diffuse Large B-cell Lymphoma (DLBCL)
17%
Lung Cancer
17%
Clinical Outcomes
17%
Mantle Cell Lymphoma
17%
Lymphoma
16%
NCCN Guidelines
16%
Doxorubicin
16%
Follicular Lymphoma
16%
Gene Expression
15%
Older Adults
15%
Overall Response Rate
15%
High Risk
15%
Pancreatic Cancer
15%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
14%
Triple-negative Breast Cancer
14%
Complete Response
14%
Tumor Cells
14%
Radiation Therapy
14%
Gemcitabine
14%
Oncology
14%
Cyclophosphamide
14%
Solid Tumors
14%
Median Overall Survival
14%
Macrophages
14%
Partial Response
13%
Hematological Malignancies
13%
Brentuximab Vedotin
13%
Placebo
13%
Chimeric Antigen Receptor T Cells (CAR-T)
13%
Lenalidomide
13%
Phase I Study
12%
Programmed Death-ligand 1 (PD-L1)
12%
Cisplatin
12%
Melanoma
12%
Hodgkin Lymphoma
12%
Colorectal Cancer
12%
Malignancy
12%
Docetaxel
12%
Prostate Cancer
12%
Disease Progression
12%
Hematopoietic Cell Transplantation
12%
Bortezomib
12%
Next-generation Sequencing
12%
Human Epidermal Growth Factor Receptor 2 (HER2)
12%
Older Patients
11%
Pancreatic Ductal Adenocarcinoma
11%
Transplantation
11%
Complete Remission
11%
Newly Diagnosed
11%
Neutropenia
11%
Cancer Types
11%
Response Rate
11%
Median Progression-free Survival
11%
Monotherapy
11%
Mouse Model
11%
Somatic mutation
11%
Pembrolizumab
11%
Paclitaxel
11%
Relapsed or Refractory multiple Myeloma
11%
Glioblastoma
10%
Tumor Microenvironment
10%
Carboplatin
10%
Randomized Phase II Trial
10%
Previously Treated
10%
Tumor Growth
10%
Apoptosis
10%
Metastasis
10%
Virus
10%
Clonal Hematopoiesis
10%
Medicine and Dentistry
Neoplasm
100%
Diseases
74%
Malignant Neoplasm
66%
Overall Survival
62%
Breast Cancer
56%
Hematopoietic Cell
40%
Multiple Myeloma
36%
Progression Free Survival
35%
Acute Myeloid Leukemia
33%
Cancer
32%
Clinical Trial
32%
Non Small Cell Lung Cancer
30%
Oncology
29%
Immunotherapy
24%
T Cell
24%
Metastatic Carcinoma
24%
Radiation Therapy
22%
Adverse Event
21%
Cell Transplantation
21%
Transplantation
20%
Lung Cancer
20%
Arm
20%
Rituximab
20%
Non-Hodgkin Lymphoma
19%
Biological Marker
18%
Targeted Therapy
17%
Leukemia
16%
Hazard Ratio
16%
Hodgkin's Lymphoma
16%
Recurrent Disease
15%
Diffuse Large B-Cell Lymphoma
15%
Melanoma
15%
Prostate Cancer
15%
Myelodysplastic Syndrome
15%
Mantle Cell Lymphoma
14%
Surgery
14%
Immunity
13%
Pancreas Cancer
13%
Metastatic Breast Cancer
12%
Pancreas Adenocarcinoma
11%
Cancer Cell
11%
Tumor Progression
11%
B Cell
11%
Follicular Lymphoma
11%
Doxorubicin
10%
Solid Malignant Neoplasm
10%
Human Immunodeficiency Virus
10%
Tumor Cell
10%
Hematopoiesis
10%
Cancer Therapy
10%
Placebo
10%
Granulocyte Colony Stimulating Factor
10%
Connective Tissue Cancer
10%
Triple Negative Breast Cancer
10%
Stem Cell
10%
Phase II Trials
10%
Pembrolizumab
9%
Cisplatin
9%
Colorectal Carcinoma
9%
Positron Emission Tomography
9%
In Vitro
9%
Cyclophosphamide
9%
Systemic Therapy
9%
Lenalidomide
9%
Paclitaxel
9%
Brentuximab Vedotin
9%
Quality of Life
9%
Hematologic Malignancy
9%
Diagnosis
8%
Gemcitabine
8%
Acute Lymphoblastic Leukemia
8%
Stem Cell Transplant
8%
Drug Megadose
8%
Small Cell Lung Cancer
8%
Receptor
8%
Systematic Review
8%
Macrophage
8%
Chemoradiotherapy
8%
B-Cell Chronic Lymphocytic Leukemia
8%
Hormone Therapy
8%
Natural Killer Cell
8%
Infection
8%
Neutropenia
8%
Xenograft
7%
Peripheral T-Cell Lymphoma
7%
Chimeric Antigen Receptor T-Cell
7%
Immune Checkpoint Inhibitor
7%
Bortezomib
7%
Soft Tissue Sarcoma
7%
Circulating Tumor DNA
7%
Health Care Cost
7%
Next Generation Sequencing
7%
Glioblastoma
7%
Epidermal Growth Factor Receptor
7%
Disease Free Survival
7%
Gene Expression
7%
Hematopoietic Stem Cell Transplantation
7%
Graft Versus Host Reaction
7%
Minimal Residual Disease
7%
Large-Cell Lymphoma
7%